26 July 2018  
EMA/CHMP/297226/2018 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Mekinist 
trametinib  
On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal 
product Mekinist. The marketing authorisation holder for this medicinal product is Novartis 
Europharm Limited. 
The CHMP adopted an extension to an existing indication as follows: 
“Adjuvant treatment of melanoma 
Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult 
patients with Stage III melanoma with a BRAF V600 mutation, following complete 
resection.” 
For information, the full indications for Mekinist will be as follows2: 
“Melanoma 
Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment 
of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation 
(see sections 4.4 and 5.1). 
Trametinib monotherapy has not demonstrated clinical activity in patients who have 
progressed on a prior BRAF inhibitor therapy (see section 5.1). 
Adjuvant treatment of melanoma 
Trametinib in combination with dabrafenib is indicated for the adjuvant treatment 
of adult patients with Stage III melanoma with a BRAF V600 mutation, following 
complete resection. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be 
issued 67 days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
Non-small cell lung cancer (NSCLC) 
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients 
with advanced non-small cell lung cancer with a BRAF V600 mutation.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment 
report (EPAR), and will be available in all official European Union languages after a decision on this 
change to the marketing authorisation has been granted by the European Commission. 
Mekinist  
EMA/CHMP/297226/2018 
Page 2/2 
 
  
  
 
 
